183 related articles for article (PubMed ID: 32224528)
1. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours.
Nagare RP; Sneha S; Sidhanth C; Roopa S; Murhekar K; Shirley S; Swaminathan R; Sridevi V; Ganesan TS
Cancer Biomark; 2020; 28(3):397-408. PubMed ID: 32224528
[TBL] [Abstract][Full Text] [Related]
2. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
3. CD44
Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
[TBL] [Abstract][Full Text] [Related]
4. Is sphere assay useful for the identification of cancer initiating cells of the ovary?
Martínez-Serrano MJ; Caballero-Baños M; Vilella R; Vidal L; Pahisa J; Martínez-Roman S
Int J Gynecol Cancer; 2015 Jan; 25(1):12-7. PubMed ID: 25365589
[TBL] [Abstract][Full Text] [Related]
5. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
[TBL] [Abstract][Full Text] [Related]
6. CD24 and Nanog identify stem cells signature of ovarian epithelium and cysts that may develop to ovarian cancer.
Schreiber L; Raanan C; Amsterdam A
Acta Histochem; 2014 Mar; 116(2):399-406. PubMed ID: 24103524
[TBL] [Abstract][Full Text] [Related]
7. Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma.
Jin Y; Zou Y; Wan L; Lu M; Liu Y; Huang G; Wang J; Xi Q
Mol Med Rep; 2018 Apr; 17(4):5409-5415. PubMed ID: 29393455
[TBL] [Abstract][Full Text] [Related]
8. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
11. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
12. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
[TBL] [Abstract][Full Text] [Related]
13. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Connor EV; Saygin C; Braley C; Wiechert AC; Karunanithi S; Crean-Tate K; Abdul-Karim FW; Michener CM; Rose PG; Lathia JD; Reizes O
J Ovarian Res; 2019 Nov; 12(1):112. PubMed ID: 31735168
[TBL] [Abstract][Full Text] [Related]
14. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.
Starbuck KD; Szender JB; Duncan WD; Morrell K; Etter JL; Zsiros E; Odunsi K; Moysich K; Eng KH
PLoS One; 2018; 13(11):e0206913. PubMed ID: 30418985
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
17. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
18. Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients.
Tamkovich SN; Yunusova NV; Tugutova E; Somov AK; Proskura KV; Kolomiets LA; Stakheeva MN; Grigor’eva AE; Laktionov PP; Kondakova IV
Asian Pac J Cancer Prev; 2019 Jan; 20(1):255-262. PubMed ID: 30678441
[TBL] [Abstract][Full Text] [Related]
19. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
20. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity.
Jaggupilli A; Elkord E
Clin Dev Immunol; 2012; 2012():708036. PubMed ID: 22693526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
